BPC-157Body Protection Compound-157
A pentadecapeptide derived from human gastric juice, studied for cytoprotective and tissue-remodeling mechanisms.
Vendors
| Vendor | Tier | Products / options | Salt | Purity | COA | $/mg | |
|---|---|---|---|---|---|---|---|
| Peptide Crafters | A | BPC-1575mg, 10mg | Acetate | 99.8% | Finnrick7d | $5.00–6.00 | View |
| Atomik Labz | A | BPC-1575mg, 10mg | Acetate | 99.2% | Finnrick14d | $5.31–7.02 | View |
| Skye Peptides | A | BPC-1575mg, 10mg | Acetate | 99.6% | Finnrick12d | $5.50–6.00 | View |
| Eternal Peptides | A | BPC-1575mg, 10mg | Acetate | 99.3% | Janoshik12d | $6.50–8.00 | View |
Reviews
Grade 2 hamstring tear. Combined with TB-500. Returned to training in 5 weeks instead of expected 8-10. Very impressed with the recovery speed.
Used for chronic Achilles tendinopathy after 6 months of failed PT. 250mcg 2x daily subq near the tendon. Noticeable improvement in pain and mobility by week 3. Fully resolved by week 8.
Took oral BPC-157 for persistent gastritis. 500mcg twice daily for 4 weeks. Significant reduction in symptoms. Minor nausea first few days but it passed.
Practical Information
Generally well-tolerated in studies. Some users report mild nausea or dizziness at higher doses. Injection site reactions (redness, swelling) occasionally reported with subcutaneous administration.
No serious adverse events reported in animal studies at doses up to 10mg/kg. Limited human safety data available. Theoretical concerns about promoting growth of existing tumors (not demonstrated).
Active cancer or history of cancer (theoretical). Pregnancy and breastfeeding (no data). Concurrent use with NSAIDs may reduce efficacy. Not recommended for children.
Reference
Regulatory status may change. Always verify current regulations in your jurisdiction before purchase.